Streetbeat News

Stock Prices

DOCU

DocuSign Inc (NASDAQ:DOCU) reported better-than-expected Q4 financial results, with revenue increasing 8% year-over-year to $712.4 million, surpassing the consensus estimate. Earnings were 76 cents per share, beating estimates of 64 cents. The company forecasts Q1 revenue of $704 million to $708 million and FY 2025 revenue between $2.915 billion and $2.927 billion, both above estimates. Following the report, analysts from Evercore ISI Group, B of A Securities, Wells Fargo, and Piper Sandler adjusted their price targets on DocuSign.

Portfolio Pulse from Avi Kapoor

March 08, 2024 | 1:06 pm

OCUP

Ocuphire Pharma (OCUP) reported a Q4 2023 GAAP EPS of $(0.210), missing the $(0.050) estimate by 320%. Quarterly sales were $1.700M, missing the $5.349M estimate by 68.22%, and representing a 95.73% decrease from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:05 pm

OVID

Ovid Therapeutics reported Q4 2023 GAAP EPS of $(0.220), missing the $(0.100) estimate, but its sales of $141.562K exceeded the $56.500K estimate, marking a 205.88% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:04 pm

CRMT

America's Car-Mart (NASDAQ:CRMT) reported a significant miss in both earnings and sales for Q3. Earnings per share were $(1.34), missing estimates by 106.15% and marking a 682.61% decrease from the previous year. Sales were $299.61M, missing estimates by 14.63% and showing an 8.24% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 1:03 pm

GPS

Gap Inc. (NYSE:GPS) reported Q4 earnings that surpassed expectations with a revenue increase of 1% year-over-year to $4.30 billion and earnings of 49 cents per share, beating estimates. The company expects flat net sales for Q1 and full-year 2024 but anticipates margin expansion. Following the report, several analysts raised their price targets on Gap shares, which gained 1.4% to close at $19.33.

Portfolio Pulse from Avi Kapoor

March 08, 2024 | 12:57 pm

BIIB

Biogen shares increased in value following the FDA's postponement of its decision on Eli Lilly's Alzheimer's drug, Donanemab.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:57 pm

NYAX

Nayax announced the pricing of a public offering of 3,130,435 shares at $26 per share, leading to a decrease in its stock price.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:54 pm

GE

JP Morgan analyst Seth Seifman upgrades General Electric (GE) from Neutral to Overweight and increases the price target from $166 to $180.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:54 pm

GPS

Wells Fargo analyst Ike Boruchow has maintained an Overweight rating on Gap (NYSE:GPS) and increased the price target from $24 to $25.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:50 pm

KNTK

JP Morgan analyst Jeremy Tonet upgraded Kinetik Holdings (NYSE:KNTK) from Neutral to Overweight and increased the price target from $38 to $40.

Portfolio Pulse from Benzinga Newsdesk

March 08, 2024 | 12:49 pm